Table 3. Overall median PFS and by subgroups.
| Characteristic | Median survival (95% CI) |
|---|---|
| Overall | 21.16 (17.19–27.14) |
| IMDC risk groups | |
| Favorable | 27.14 (21.82–NA) |
| Intermediate | 17.19 (12.69–25.88) |
| IMDC risk factors | |
| 0 | 27.14 (21.82–NA) |
| 1 | 25.88 (17.19–NA) |
| 2 | 11.21 (7.17–19.74) |
| Baseline R/M: location | |
| Single lung metastasis | 25.88 (23.07–NA) |
| Single bone metastasis | 21.16 (6.15–NA) |
| Multiple metastases including lung | 17.98 (13.69–NA) |
| Multiple metastases excluding lung | 11.21 (5.59–NA) |
| Single metastasis excluding lung and bone | 31.01 (22.28–NA) |
| Baseline number of R/M organs | |
| 1 | 25.92 (23.07–31.93) |
| 2 | 17.98 (12.07–NA) |
| ≥3 | 12.30 (8.53–NA) |
| Age category | |
| <65 years | 22.28 (17.98–31.93) |
| ≥65 years | 18.45 (15.34–29.65) |
| Local treatment | |
| No | 19.67 (16.10–25.92) |
| Primary site | 31.01 (23.07–NA) |
| Metastasis site | 15.37 (9.52–NA) |
| Number of R/M location | |
| No R/M | 12.15 (5.02–NA) |
| Single | 25.92 (23.07–31.93) |
| Multiple | 14.64 (12.07–27.14) |
| Treatment response | |
| SD | 19.67 (16.10–28.10) |
| PD | 2.20 (1.98–8.20) |
| PR | 31.01 (25.92–NA) |
PFS, progression free survival; IMDC, International Metastatic renal cell carcinoma Database Consortium; R/M, relapse/metastasis; SD, stable disease; PD, progressive disease; PR, partial response; CI, confidence interval.